Compare · CNMD vs LIVN
CNMD vs LIVN
Side-by-side comparison of CONMED Corporation (CNMD) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.24B, about 3.8x CNMD ($1.11B).
- Over the past year, CNMD is down 37.9% and LIVN is up 62.1% - LIVN leads by 100.0 points.
- CNMD has been more active in the news (13 items in the past 4 weeks vs 5 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 14 for CNMD).
- Company
- CONMED Corporation
- LivaNova PLC
- Price
- $36.92+7.00%
- $77.19+3.15%
- Market cap
- $1.11B
- $4.24B
- 1M return
- +0.50%
- +7.39%
- 1Y return
- -37.91%
- +62.13%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- News (4w)
- 13
- 5
- Recent ratings
- 14
- 20
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest CNMD
- CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Director Bronson David M. converted options into 668 shares, increasing direct ownership by 4% to 17,909 units (SEC Form 4)
- Director Council Laverne H converted options into 668 shares, increasing direct ownership by 17% to 4,716 units (SEC Form 4)
- SEC Form 4 filed by Director Kelderman Kim
- Director Farkas Charles converted options into 668 shares, increasing direct ownership by 4% to 15,527 units (SEC Form 4)
- Director Kaye Mark converted options into 668 shares, increasing direct ownership by 439% to 820 units (SEC Form 4)
- Director Schwarzentraub Barbara J converted options into 668 shares, increasing direct ownership by 15% to 5,012 units (SEC Form 4)
- Amendment: New insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)
- New insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)
- CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest LIVN
- LivaNova Appoints Anne Liddy as Chief Legal Officer
- SEC Form SD filed by LivaNova PLC
- Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)
- LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC